ArticleThe Journal of pathology2026
Exosomal lncRNA PVT1 promotes fibroblast activation and colon cancer progression via miR-23b-5p signaling.
Article in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colon cancer progression is closely associated with the tumor microenvironment, where cancer-associated fibroblasts (CAFs) play a pivotal role. Exosomal long non-coding RNAs (lncRNAs) are known to modulate the tumor stroma, but the role of lncRNA PVT1 (plasmacytoma variant translocation 1) in exosome-mediated fibroblast activation in colon cancer remains poorly understood. This study demonstrated significantly elevated PVT1 levels in colon cancer tissues. Mechanistically, hypoxia/reoxygenation (H/R) induced the recruitment of HIF-1α to the PVT1 promoter, directly activating its transcription and subsequent exosomal loading. Exosomes derived from H/R-treated colon cancer cells promoted fibroblast activation into a CAF phenotype. PVT1 was found to sponge miR-23b-5p, thereby upregulating a network of target genes. Importantly, silencing of MAPK13, a key downstream target, significantly abrogated the PVT1-mediated fibroblast-to-CAF transformation. In vivo experiments confirmed that exosomal PVT1 enhanced CAF infiltration and tumor growth, whereas these effects were reversed by either restoring miR-23b-5p expression or knocking out PVT1. These findings uncover a novel mechanism whereby H/R-induced exosomal PVT1 promotes fibroblast activation and CAF transformation via the miR-23b-5p signaling axis, providing potential diagnostic biomarkers and therapeutic targets for modulating the tumor stroma in colon cancer. © 2026 The Pathological Society of Great Britain and Ireland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.